ImmuCell Corporation Proceeds from Issuance or Sale of Equity
ImmuCell Corporation (ICCC) reported Proceeds from Issuance or Sale of Equity of $10.00 million for the 1-month period ending 2015-10-28, per its 10-Q/A filed 2022-11-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2022-11-21
- 2015-10-28: Proceeds from Issuance or Sale of Equity 1 month $10.00M.
| Period end | Proceeds from Issuance or Sale of Equity 1 month |
|---|---|
| 2015-10-28 | $10.00M 10-Q/A · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |